ibi351
innovent biologics
['solid tumor', 'innovent biologics', 'innovent', 'innovent_2011', 'innovent bio']
innovent presents clinical data of phase i study for ibi351 (kras g12c inhibitor) as monotherapy for solid tumors at the 2022 american society of clinical oncology (asco) annual meeting
To develop and commercialize high-quality biopharmaceuticals that are affordable to ordinary people.